FIDES-02 Data Fail to Support the Development of Derazantinib in Metastatic Urothelial Cancer
Andrea Necchi, MD, discusses the efficacy and safety data reported from the FIDES-02 study, explains the clinical relevance of these data despite the trial’s negative result, and highlights several other influential studies presented at the 2023 Genitourinary Cancers Symposium.
Source: onclive.com